Sara Lubitz, MD, reviews the modern landscape of chronic hypoparathyroidism, unmet needs with conventional calcium and vitamin D therapy, and the shift toward parathyroid hormone replacement.

Sara Lubitz, MD, explains how palopegteriparatide delivers sustained PTH1 receptor activation and reviews phase 3 data demonstrating durable biochemical control and improved renal and QoL outcomes.

Sara Lubitz, MD, discusses guideline-based criteria for selecting patients for PTH therapy, treatment goals, and how palopegteriparatide may reduce renal complications and pill burden.

Sara Lubitz, MD, offers practical advice on transitioning appropriate patients to palopegteriparatide, including the dose-finding phase, laboratory monitoring, and considerations for women of childbearing potential.

Sara Lubitz, MD, outlines key research priorities, emerging PTH-axis therapies, and her expectation that hormone replacement will become the new standard of care in chronic hypoparathyroidism.